- Home
- RMTI vs VIGL Comparison
RMTI vs VIGL Comparison
Compare RMTI & VIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMTI
- VIGL
- Stock Information
- Founded
- RMTI 1994
- VIGL 2020
- Country
- RMTI United States
- VIGL United States
- Employees
- RMTI N/A
- VIGL N/A
- Industry
- RMTI Biotechnology: Pharmaceutical Preparations
- VIGL Biotechnology: Pharmaceutical Preparations
- Sector
- RMTI Health Care
- VIGL Health Care
- Exchange
- RMTI Nasdaq
- VIGL Nasdaq
- Market Cap
- RMTI 138.1M
- VIGL 125.3M
- IPO Year
- RMTI 1998
- VIGL 2022
- Fundamental
- Price
- RMTI $3.64
- VIGL $3.44
- Analyst Decision
- RMTI Strong Buy
- VIGL Buy
- Analyst Count
- RMTI 2
- VIGL 5
- Target Price
- RMTI $7.00
- VIGL $16.60
- AVG Volume (30 Days)
- RMTI 788.1K
- VIGL 94.8K
- Earning Date
- RMTI 11-12-2024
- VIGL 11-05-2024
- Dividend Yield
- RMTI N/A
- VIGL N/A
- EPS Growth
- RMTI N/A
- VIGL N/A
- EPS
- RMTI N/A
- VIGL N/A
- Revenue
- RMTI $94,372,000.00
- VIGL N/A
- Revenue This Year
- RMTI $22.20
- VIGL N/A
- Revenue Next Year
- RMTI $8.76
- VIGL N/A
- P/E Ratio
- RMTI N/A
- VIGL N/A
- Revenue Growth
- RMTI 24.58
- VIGL N/A
- 52 Week Low
- RMTI $1.16
- VIGL $2.47
- 52 Week High
- RMTI $4.57
- VIGL $9.24
- Technical
- Relative Strength Index (RSI)
- RMTI 52.11
- VIGL 50.19
- Support Level
- RMTI $3.47
- VIGL $3.20
- Resistance Level
- RMTI $3.97
- VIGL $3.48
- Average True Range (ATR)
- RMTI 0.29
- VIGL 0.18
- MACD
- RMTI -0.09
- VIGL 0.02
- Stochastic Oscillator
- RMTI 15.45
- VIGL 46.58
About RMTI Rockwell Medical Inc.
Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. It is a supplier of liquid bicarbonate concentrates, and acid and dry bicarbonate concentrates for dialysis patients in the United States. The company's products include CitraPure citric acid concentrate, RenalPure liquid acid concentrate, and SteriLyte bicarbonate concentrate among others.
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.